未经评估：RUNX1-RUNXT1，PML-RARA的分布，CBFB-MYH11,BCR-ABL1p210,和KMT2A-MLLT3在拉丁美洲许多国家的急性髓细胞性白血病(AML)儿科人群中的应用在很大程度上是未知的.因此,我们旨在调查这些融合基因在来自墨西哥城的新生AML儿童中的频率，是世界上急性白血病发病率最高的国家之一。此外,我们探讨了它们对治疗第一年死亡率的影响.
未经评估：我们回顾性分析了RUNX1-RUNXT1，PML-RARA的存在，CBFB-MYH11,BCR-ABL1p210,和KMT2A-MLLT3通过RT-PCR在2019年至2021年间在墨西哥城的9家医院中诊断为从头AML的77名患者（<18岁）中。
UNASSIGNED：融合基因的总体频率为50.7%；RUNX1-RUNXT1（22.1%）和PML-RARA（20.8%）最为普遍，其次是CBFB-MYH11（5.2％）和BCR-ABL1p210（2.4％）。未检测到KMT2A-MLLT3。PML-RARA患者的生存率最低，早期死亡率高。然而,需要更多的研究来评估分析的融合基因对墨西哥儿童AML患者总体生存率的影响.
未经证实：墨西哥城患有AML的儿科人群有AML1-ETO的频率，PML-RARA,CBFB-MYH11和BCR-ABL1p210与世界其他人群相似。BCR-ABL1p210和CBFB-MYH11患者很少或没有死亡，而未检测到MLL-AF9。尽管PML-RARA患者的生存率低，早期死亡率高，需要进一步的研究来确定这些融合基因对该拉丁裔人群的长期影响.
UNASSIGNED: The distribution of RUNX1-RUNXT1, PML-RARA, CBFB-MYH11, BCR-ABL1p210 , and KMT2A-MLLT3 in the pediatric population with acute myeloid leukemia (AML) in many countries of Latin America is largely unknown. Therefore, we aimed to investigate the frequency of these fusion genes in children with de novo AML from Mexico City, which has one of the highest incidence rates of acute leukemia in the world. Additionally, we explored their impact in mortality during the first year of treatment.
UNASSIGNED: We retrospectively analyzed the presence of RUNX1-RUNXT1, PML-RARA, CBFB-MYH11, BCR-ABL1p210 , and KMT2A-MLLT3 by RT-PCR among 77 patients (<18 years) diagnosed with de novo AML between 2019 and 2021 in nine Mexico City hospitals.
UNASSIGNED: The overall frequency of the fusion genes was 50.7%; RUNX1-RUNXT1 (22.1%) and PML-RARA (20.8%) were the most prevalent, followed by CBFB-MYH11 (5.2%) and BCR-ABL1p210 (2.4%). KMT2A-MLLT3 was not detected. Patients with PML-RARA showed the lowest survival with high early mortality events. However, more studies are required to evaluate the impact of analyzed fusion genes on the overall survival of the Mexican child population with AML.
UNASSIGNED: The pediatric population of Mexico City with AML had frequencies of AML1-ETO, PML-RARA, CBFB-MYH11, and BCR-ABL1p210 similar to those of other populations around the world. Patients with BCR-ABL1p210 and CBFB-MYH11 were few or did not die, while those with MLL-AF9 was not detected. Although patients with PML-RARA had a low survival and a high early mortality rate, further studies are needed to determine the long-term impacts of these fusion genes on this Latino population.
PDF(Pubmed)